TimesSquare Capital Management LLC Acquires 8,285 Shares of argenex SE $ARGX

TimesSquare Capital Management LLC raised its holdings in argenex SE (NASDAQ:ARGX) by 6.6% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 133,580 shares of the company’s stock after purchasing an additional 8,285 shares during the period. TimesSquare Capital Management LLC owned approximately 0.22% of argenex worth $73,632,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently made changes to their positions in the business. Millennium Management LLC raised its position in shares of argenex by 316.9% in the first quarter. Millennium Management LLC now owns 268,604 shares of the company’s stock valued at $158,977,000 after buying an additional 204,180 shares in the last quarter. BNP Paribas Financial Markets grew its position in argenex by 1,203.4% during the first quarter. BNP Paribas Financial Markets now owns 133,359 shares of the company’s stock worth $78,931,000 after buying an additional 123,127 shares in the last quarter. Braidwell LP increased its stake in argenex by 99.2% during the 1st quarter. Braidwell LP now owns 160,849 shares of the company’s stock worth $95,201,000 after acquiring an additional 80,083 shares during the period. Lord Abbett & CO. LLC raised its holdings in argenex by 33.2% in the 1st quarter. Lord Abbett & CO. LLC now owns 274,700 shares of the company’s stock valued at $162,585,000 after acquiring an additional 68,498 shares in the last quarter. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. lifted its position in shares of argenex by 244.6% during the 2nd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 87,414 shares of the company’s stock valued at $48,184,000 after acquiring an additional 62,044 shares during the period. Institutional investors and hedge funds own 60.32% of the company’s stock.

argenex Price Performance

ARGX stock opened at $889.64 on Wednesday. The stock has a market cap of $54.78 billion, a price-to-earnings ratio of 38.20, a P/E/G ratio of 0.90 and a beta of 0.45. The company has a 50 day simple moving average of $789.68 and a 200 day simple moving average of $667.22. argenex SE has a 1 year low of $510.05 and a 1 year high of $893.52.

argenex (NASDAQ:ARGX) last posted its earnings results on Thursday, October 30th. The company reported $4.40 earnings per share for the quarter, topping analysts’ consensus estimates of $4.37 by $0.03. argenex had a net margin of 41.58% and a return on equity of 29.78%. The firm had revenue of $1.12 billion for the quarter, compared to analysts’ expectations of $1.07 billion. On average, equities research analysts anticipate that argenex SE will post 3.13 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the company. Weiss Ratings reaffirmed a “hold (c)” rating on shares of argenex in a research note on Wednesday, October 8th. Deutsche Bank Aktiengesellschaft lowered shares of argenex from a “buy” rating to a “hold” rating in a report on Thursday, September 11th. JPMorgan Chase & Co. upped their price target on shares of argenex from $830.00 to $925.00 and gave the stock an “overweight” rating in a report on Friday, November 7th. Evercore ISI lifted their price objective on shares of argenex from $775.00 to $910.00 and gave the company an “outperform” rating in a research note on Friday, October 31st. Finally, Morgan Stanley upped their target price on argenex from $766.00 to $1,040.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 1st. One investment analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $879.28.

About argenex

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.